[Adverse effects of selective serotonin reuptake inhibitors use during the third trimester of pregnancy and prevention guidelines].
Selective Serotonin Reuptake Inhibitors (SSRIs) have become the drug of choice for the treatment of depression and have shown to be effective in the treatment for other mental disorders. Recently, several articles have reported about the adverse effects observed in newborns after maternal exposure to these drugs during the last trimester of pregnancy. In this work, a review of literature is presented, regarding the above mentioned adverse effects. Moreover, some guidelines for the rational use of these drugs during the last trimester of pregnancy and for the management of prenatally exposed newborns are provided.
Mejías
Consuelo
C
Sección de Teratología Clínica y Servicios de Información Telefónica sobre Teratógenos (SITTE y SITE), Centro de Investigación sobre Anomalías Congénitas (CIAC), Instituto de Salud Carlos III, Madrid, España. site@isciii.es
Rodríguez-Pinilla
Elvira
E
Fernández Martín
Paloma
P
Martínez-Frías
María Luisa
ML
D000328:Adult; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D009357:Neonatal Abstinence Syndrome / Q000209:etiology* / Q000517:prevention & control*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011263:Pregnancy Trimester, Third; D020230:Serotonin Syndrome / Q000209:etiology* / Q000517:prevention & control; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000506:poisoning / Q000627:therapeutic use
D017367:Selective Serotonin Reuptake Inhibitors